Bayer's Nubequa Posts Significant OS Data as it Fights for Market Share in Prostate Cancer | BioSpace

Bayer's Nubequa Posts Significant OS Data as it Fights for Market Share in Prostate Cancer | BioSpace: The new data should give Bayer’s Nubequa some energy to go after market share held by other drugs approved to treat prostate cancer, including Pfizer’s Xtandi.

Comments

Popular posts from this blog

Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily